[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"proton-magnetic-resonance-spectroscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:proton-magnetic-resonance-spectroscopy":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100492429","phase-1-coffee-and-metabolites-modulating-the-gut-microbiome-in-colorectal-cancer-100492429",false,"NCT05692024","COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER","COMMENCER: COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER","COMMENCER","Inclusion Criteria:\n\nParticipants must meet the following criteria on screening examination to be eligible to participate in the study:\n\n* Participants must have histologically confirmed stage I, II, or III colon or rectal adenocarcinoma and have completed standard treatment (including surgery, chemotherapy and radiotherapy) at least 2 months ago.\n* Age 18 years or older.\n* This study will only include adult participants because colorectal carcinogenesis in children is more likely to be related to a cancer predisposition syndrome with distinct biological mechanisms compared with sporadic colorectal cancer in adults.\n* The effects of coffee on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Subjects must be able and willing to follow study procedures and instructions.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nParticipants who exhibit any of the following conditions at screening will not be eligible for admission into the study.\n\n* Participants who are receiving any other investigational agents.\n* Concurrent use of other anti-cancer therapy, including chemotherapy agents, targeted agents, biological agents, immunotherapy, or investigational agents not otherwise specified in this protocol.\n* Regularly consuming more than 2 cups of coffee ( 8 oz) per day for at least 3 days a week in the past month.\n* Current or recent use (within 1 month) of any coffee supplements (e.g., green coffee extracts).\n* History of diagnosed conditions that may be worsen by coffee, including arrhythmias, insomnia, tremors, tics, generalized anxiety disorder, bipolar disease, panic attacks, Tourette's, epilepsy or overactive bladder.\n* History of adverse reactions to coffee or intolerance of coffee consumption.\n* Inability or unwillingness to swallow capsules.\n* History of malabsorption or uncontrolled vomiting or diarrhea, or any other disease that could interfere with absorption of oral medications.\n* Any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness\u002Fsocial situations that, in the opinion of the investigator, may increase the risks associated with study participation or study treatment, limit compliance with study requirements, or interfere with the interpretation of study results.\n* Pregnant or breastfeeding. The effects of coffee on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.\n\nShould a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Similarly, lactating women are excluded from this study because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with coffee. Consequently, breastfeeding should be discontinued if the mother is enrolled on the study.\n\n* Presence of synchronous (at the same time) malignancy for which the patient is currently receiving active treatment.\n* Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.",[28,29,30,31,32,33,34],"Colorectal Cancer","Coffee","Gastrointestinal Microbiome","Stenosis","Fibrosis, Liver","Ultrasound Elastography","Proton Magnetic Resonance Spectroscopy",[36,37,38,29,39],"Liver fat","Gut microbiome","Colorectal cancer","Tumor biopsy","RECRUITING","2026-04-29",{"date":43,"type":44},"2026-05-05","ACTUAL",{"date":46,"type":44},"2024-03-21",{"date":48,"type":21},"2028-08-31",{"name":50,"class":51},"Massachusetts General Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":52},"100550669","study-of-the-relationship-between-clinical-imaging-and-biological-data-in-patients-with-squamous-cell-carcinoma-of-the-tongue-100550669","NCT06450080","Study of the Relationship Between Clinical, Imaging and Biological Data in Patients With Squamous Cell Carcinoma of the Tongue","ClimaBio","Inclusion Criteria:\n\nPatients:\n\n* Patients from the maxillofacial surgery department of the Amiens-Picardie University Hospital treated for histologically confirmed squamous cell carcinoma of the tongue\n* Patients who have not yet been treated, either surgically or by neoadjuvant treatment\n* Patients with a tumor of minimum dimensions of 15 mm in long axis\n* Patients without contraindication to MRI\n* Patients over 18 years old\n* Patients who have provided free and informed written consent\n* Patients benefiting from a social security system\n\nHealthy volunteers:\n\n* Subjects without a history of cancer of the upper aerodigestive tract\n* Subjects without contraindication to MRI\n* Subjects over 18 years old\n* Subjects who have provided free and informed written consent\n* Subjects benefiting from a social security system\n\nExclusion Criteria:\n\n* Patients:\n* Patients with a lingual tumor measuring less than 15 mm in long axis\n\nPatients and healthy volunteers:\n\n* Patients with other histological types of cancer, or other locations\n* Subjects with a contraindication to MRI\n* Subjects under 18 years old\n* Pregnant or breastfeeding women\n* Persons under guardianship, curators, protection of justice or deprived of liberty",true,{"count":62,"type":21},60,[64],"NA","Squamous cell carcinoma (SCC) could be a very aggressive cancer and has a bad prognosis if not detected early and thus is associated with high mortality. The development of simple and reliable biomarkers for the early detection of SCC is one of the solutions to better diagnose, treat these tumors, evaluate and monitor treatments, and hence reduce mortality. In a previous work, the investigators demonstrated the ability of Proton Magnetic resonance spectroscopy (1H-MRS) to non-invasively assess spectroscopic and metabolic profiles of tongue tissue in healthy subjects. In the present work, the investigators challenge the use of in-vivo 1H-MRS as a potential method for non-invasive metabolic monitoring of patients with squamous cell carcinoma of the tongue undergoing therapy. Thus the main objective is to study the spectroscopic and metabolic differences, e.g. including variation in the metabolite TMA-Cho (trimethylamine-choline), of tongue tissue between healthy subjects and in patients with squamous cell carcinoma of the tongue, before and after surgery.",[67,68,34,69],"Soft Tissue Tumors of the Tongue","Squamous Cell Carcinoma","Transcriptomics",[71,68,72,73,74,75,69],"Tongue tissue","proton magnetic resonance spectroscopy","1H-MRS","spectroscopic and metabolic profile","noninvasive biomarkers","2024-06-04",{"date":78,"type":44},"2024-06-10",{"date":80,"type":44},"2024-03-27",{"date":82,"type":21},"2026-06",{"name":84,"class":51},"Centre Hospitalier Universitaire, Amiens"]